Gilead and one other company have treatment in clinical testing currently with the hope of good results in early may. The other company it's a malaria drug that is currently in production with Gilead it's a drug they developed for a different outbreak. The hope is if all goes perfectly the drug can get approved and to market by May. The hopeful May time frame was mentioned on CNBC the other day. This requires everything to go prefect and get everything fast tracked. They are currently using it in Washington (state).
According to CDC director Dr. Robert Redfield in congressional testimony.
fortune.com
Here's another article. It's experimental but appears to already be being used in other viruses that are similar to this one. Hence the reason for the hope.
Many see remdesivir as one of few drugs that has reasonable prospect of helping patients
www.theguardian.com
Here's one more:
A mix of legacy drugmakers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel...
www.marketwatch.com
Type: Treatment
Stage: Phase 3 clinical trials
Name: remdesivir
Background: Gilead is a longtime drug maker that is best known for developing the first major cure for hepatitis-C in Sovaldi, a therapy that changed the standard of care for that disease but also kicked off the national debate about drug pricing. The company has experience developing and marketing HIV drugs, including Truvada for pre-exposure prophylaxis (PrEP), its preventive HIV medicine. Along with U.S. trials, Gilead is conducting a randomized, controlled clinical trial in Wuhan, testing remdesivir as a treatment for mild to moderate forms of pneumonia in people with the virus. The trial was given the go-ahead by China’s Food and Drug Administration in February.
Clinical trials:
1. On Feb. 21, the National Institute of Allergy and Infectious Diseases started enrolling patients in a
randomized, double-blind, placebo-controlled Phase 3 trial evaluating 394 hospitalized patients with COVID-19 at up to 50 sites worldwide. The trial is expected to conclude April 1, 2023. Sites include the National Institutes of Health in Bethesda, Md., (not recruiting), the University of Nebraska Medical Center in Omaha (recruiting), the University of Texas Medical Branch in Galveston (not recruiting), and Providence Sacred Heart Medical Center in Spokane (recruiting).
2. On March 3, Gilead said a
randomized, open-label Phase 3 trial will evaluate remdesivir in 600 patients with moderate COVID-19. The trial is expected to start enrolling patients in March, with results to come in May.
3. On March 3, Gilead said a
randomized, open-label Phase 3 trial will evaluate remdesivir in 400 patients with severe COVID-19. The trial is expected to start enrolling patients in March, with results in May.
They are treating in the Seattle, Washington area.
Facebook
Twitter
Instagram